Factor Therapeutics

A leader in advanced wound care therapeutics.

[Factor Therapeutics @Factor_Tx]

Our sincere thanks to all our shareholders, partners and the patients who participated in the study - while not the outcome we hoped for, the wider field of wound care research will benefit from the VF00102 study

[Factor Therapeutics @Factor_Tx]

Our Phase 2 results announced this morning showed that VF001 was unable to improve on standard care for healing VLUs. More information at https://t.co/PIzBYOFvNw

[Factor Therapeutics @Factor_Tx]

Factor Therapeutics has appointed a transaction advisor - see the full announcement at https://t.co/2osk3oA2vS

[Factor Therapeutics @Factor_Tx]

Treatment is finished in our Phase 2 VLU trial! Readout is now only a few weeks away https://t.co/d0lKOrZV60 #researchmatters #woundcare #phase2

[Factor Therapeutics @Factor_Tx]

Shareholder Update Q3 2018 https://t.co/tcAsNj8cms

[Factor Therapeutics @Factor_Tx]

An update on our pipeline was released today - progress in our other clinical and early research programmes. https://t.co/4InMakPOnk

[Factor Therapeutics @Factor_Tx]

CEO Ros Wilson is speaking this afternoon in Adelaide at Broker Meets Biotech #ClinicalResearch #woundcare #researchmatters #phase2

[Factor Therapeutics @Factor_Tx]

...and here’s the video of the interview with @ScottPowerSays Factor Therapeutics (ASX: FTT): Dr Rosalind Wilson, Chief Executive Officer https://t.co/uQsXJU0zwq via @YouTube

[Factor Therapeutics @Factor_Tx]

Ros recently sat down with Scott Power of Morgans to give an update on our countdown towards readout. ‘Under the microscope: Dr Rosalind Wilson, CEO of Factor Therapeutics (ASX: FTT)’ on #SoundCloud #np https://t.co/HIyzGrrWuH

[Factor Therapeutics @Factor_Tx]

Our CEO, Ros Wilson, is about to present and update at Broker Meets Biotech in Perth. View the presentation here https://t.co/iM8D2ERqKT

[Factor Therapeutics @Factor_Tx]

Presenting Factor at Bioshares as we approach readout - exciting times ahead! #bioshares #woundcare #clinicaltrials #researchmatters

[Marc Sinatra @sinatramarc]

Just released a report on Factor Therapeutics $FTT. Looks highly undervalued. NPV = 33.5 cents/share (fully diluted) prior to phase IIb readout in Q4 CY18. NPV = 52 cents after, if +ve. Multiple catalysts to get it there. It’s a good one! @biotech_daily @asxlongtail @Factor_Tx

[Factor Therapeutics @Factor_Tx]

A big thank you to everyone who helped ensure the successful recruitment of our Phase 2 clinical trial. We look forward to sharing the results with you. #ResearchMatters

[Factor Therapeutics @Factor_Tx]

Our CEO is sleeping outside tonight as part of the 2018 Vinnies CEO Sleepout #vinniesQLD #CEOSleepoutAU

[Factor Therapeutics @Factor_Tx]

Here’s our latest trial update - May was outstanding and we’re looking forward to delivering results later this year https://t.co/dxy4EWMTj7

[Factor Therapeutics @Factor_Tx]

Many thanks for those who came along to today’s AGM. Our Chairman’s address and CEO Report are available now https://t.co/BcCex4ObTm

[Factor Therapeutics @Factor_Tx]

Factor’s CEO, Ros Wilson, is taking part in the Vinnies CEO Sleepout to raise funds for people experiencing homelessness. Please support her and help fellow Australians in need. https://t.co/Gq5mYlZknJ

[Factor Therapeutics @Factor_Tx]

#SAWCSpring

[Factor Therapeutics @Factor_Tx]

Congratulations to Derek Van Lonkhuyzen on a great presentation this afternoon, sharing some of our preclinical data and highlighting the Phase 2 clinical programme

[Factor Therapeutics @Factor_Tx]

Our quarterly trial update was released this week - the study is 70% recruited as we continue to progress toward this key milestone https://t.co/CLq5VH0sqA